Cellectis (NASDAQ:CLLS) had its price target raised by Nomura to $73.00 in a report issued on Wednesday, March 14th. They currently have a buy rating on the biotechnology company’s stock.
A number of other analysts have also recently weighed in on the company. BidaskClub upgraded Cellectis from a buy rating to a strong-buy rating in a research report on Saturday, February 17th. Zacks Investment Research cut Cellectis from a hold rating to a sell rating in a report on Wednesday, February 14th. ValuEngine upgraded Cellectis from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, Oppenheimer reaffirmed an outperform rating and set a $40.00 price target on shares of Cellectis in a research note on Thursday, December 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Cellectis currently has an average rating of Hold and a consensus target price of $42.67.
Shares of CLLS stock traded down $0.17 during trading hours on Wednesday, reaching $28.83. 776,992 shares of the company’s stock were exchanged, compared to its average volume of 578,716. The firm has a market cap of $1,041.92, a PE ratio of -10.37 and a beta of 1.86. Cellectis has a fifty-two week low of $21.25 and a fifty-two week high of $38.85.
Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.12). Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%. The firm had revenue of $6.91 million for the quarter, compared to the consensus estimate of $10.10 million. equities analysts expect that Cellectis will post -2.62 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares in the last quarter. KBC Group NV bought a new position in Cellectis in the third quarter valued at approximately $366,000. HBK Investments L P bought a new position in Cellectis in the fourth quarter valued at approximately $498,000. JPMorgan Chase & Co. bought a new position in Cellectis in the third quarter valued at approximately $517,000. Finally, Advisors Asset Management Inc. grew its stake in Cellectis by 1,501.1% in the third quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock valued at $643,000 after purchasing an additional 21,181 shares in the last quarter. Institutional investors and hedge funds own 20.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Nomura Increases Cellectis (CLLS) Price Target to $73.00” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/cellectis-clls-pt-raised-to-73-00-at-nomura.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.